secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001193125-23-228131
Event type: m_and_a
Sentiment:  positive
Materiality: 0.78
Item codes: 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum acquires Travere's bile acid products Cholbam and Chenodal for $210M upfront plus $235M milestones
--------------------------------------------------------------------------------

- Completed asset purchase of Cholbam and Chenodal from Travere for $210M cash at closing, with up to $235M in sales-based milestone payments.
- Funded acquisition via $210M PIPE at $26.25/share from investors including Frazier Life Sciences, Avidity Partners, BVF Partners.
- Products treat rare liver diseases: bile acid synthesis disorders, peroxisomal disorders; Chenodal in Phase 3 for cerebrotendinous xanthomatosis (CTX).
- Travere received $210M upfront and is eligible for additional milestones; Mirum expects near-term label expansion opportunity for CTX.
- Financial statements for the acquired business to be filed as an amendment to this 8-K within 71 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/0001193125-23-228131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/d522051d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-228131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer